Jump to content
PT-141 Order A gallery-wall reading of the PT-141 (bremelanotide) literature — the approved-population data hung beside the honest tolerability picture, with field reports pinned where they belong: outside the citations.

Full studies · early notes · FDA instructions

PT-141 references carry different weight

Large studies show benefit and harm. FDA instructions set limits, while scans, animal work, and early reports answer smaller questions.

Go back to the main findingsRead the known harms

The strongest sources found modest help

The original team reported an unexpected sexual effect in 2003. The researchers wanted to know whether that effect could help patients. Later work included Phase 3, the large studies before approval, and a 52-week follow-up. A scan looked at how the brain responded.

The large studies found slightly more desire plus less distress. Common nausea continued during longer follow-up. Doctors found the same known harms but no different kind. FDA instructions set the narrow use and heart warnings, while doubtful reviews called the benefit modest.

We checked each figure against the papers and FDA record below. User accounts have no number because they don't come from studies. A number in square brackets points to the matching paper or record. Some links show only a summary unless you pay.

Full studies deserve more trust than early reports

Each source below answers a named question. The two Phase 3 papers show how much desire changed and which harms occurred. The 52-week follow-up shows whether the gain and known harms lasted. FDA instructions name the patients covered, the approved amount, and the firm warnings.

Brain scans ask where the effect may begin. Animal studies ask what happened before testing in people, but they can't prove patient benefit. Meeting reports offer early findings before a full paper appears. We treat them as leads, not final answers.

Doubtful reviews checked the large studies and called the benefit small. In 2023, journal editors placed a formal warning on a 2008 paper about older men. The editors doubted whether it could be trusted. We call that paper disputed and don't use it to prove benefit.

FDA instructions are the government's official rules, not a study. They say a 2.7-hour span cuts the blood amount in half and give the 1.75 mg amount [6]. They also list the blood-pressure warning and lasting skin darkening. Studies show what happened to people; FDA instructions say what use is allowed.

  1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. ↗
  2. Pfaus J, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101:10201-10204. ↗
  3. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. ↗
  4. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. ↗
  5. Thurston L, Hunjan T, Mills EG, Wall MB, Ertl N, Phylactou M, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. ↗
  6. U.S. Food and Drug Administration / DailyMed. Bremelanotide Injection — US Prescribing Information. 2019. ↗
  7. Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J, Williams LA. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder. J Womens Health (Larchmt). 2021;30(4):587-595. ↗
  8. Spielmans GI. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res. 2021;58(9):1085-1105. ↗
  9. Spielmans GI. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res. 2024;61(4):540-561. ↗
  10. Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299. ↗
  11. Goldstein I, et al. (122) Positive Effects of Bremelanotide on Female Sexual Arousal and Orgasm in Premenopausal Women. J Sex Med. 2025;22(Suppl 1):qdaf068.108. ↗
  12. Goldstein I, et al. (227) Use of the CNS Agent Bremelanotide in Men with Sexual Dysfunction: Results from a Sexual Medicine Clinic. J Sex Med. 2024;21(Suppl 1):qdae001.217. ↗
  13. Edinoff AN, Sanders NM, Lewis KB, Apgar TL, Cornett EM, Kaye AM, Kaye AD. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022;14(1):75-88. ↗
  14. How A, Simon JA. Novel Pharmacologic Treatments of Female Sexual Dysfunction. Clin Obstet Gynecol. 2025;68(1):10-14. ↗
  15. Vereecken S, et al. (396) Comparative Analysis of Flibanserin, Bremelanotide, and Testosterone Therapy for Female Sexual Dysfunction. J Sex Med. 2025;22(Suppl 4):qdaf320.390. ↗
  16. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79:1599-1606. ↗
  17. White WB, Myers MG, Jordan R, Lucas J. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017;35(4):761-768. ↗
  18. Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017;39(3):514-526.e14. ↗
  19. Clayton AH, Kingsberg SA, Portman D, Sadiq A, Jordan R, Lucas J, Spana C, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. ↗
  20. National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox). Bremelanotide - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (LiverTox). 2021. ↗
  21. Mestria S, Odoardi S, Frison G, Strano Rossi S. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. Drug testing and analysis. 2021. ↗
  22. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical toxicology (Philadelphia, Pa.). 2012. ↗
  23. Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes Obes Metab. 2022;24(6):1084-1093. ↗
  24. Bardhan M, Anand A, Javed A, Chilo MA, Khan N, Garg T. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases. Diseases (Basel, Switzerland). 2025. ↗
  25. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006. ↗
  26. Hedlund P. PT-141 Palatin. Current opinion in investigational drugs (London, England : 2000). 2004. ↗
  27. Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel, Switzerland). 2020. ↗